Shabir Madhi to Viral Fusion Proteins
This is a "connection" page, showing publications Shabir Madhi has written about Viral Fusion Proteins.
Connection Strength
0,890
-
A Phase 1b/2a Trial of a Half-life Extended Respiratory Syncytial Virus Neutralizing Antibody, Clesrovimab, in Healthy Preterm and Full-term Infants. J Infect Dis. 2025 Mar 17; 231(3):e478-e487.
Score: 0,246
-
Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants. N Engl J Med. 2020 07 30; 383(5):415-425.
Score: 0,179
-
Respiratory Syncytial Virus Vaccination during Pregnancy and Effects in Infants. N Engl J Med. 2020 07 30; 383(5):426-439.
Score: 0,179
-
Replacement and positive evolution of subtype A and B respiratory syncytial virus G-protein genotypes from 1997-2012 in South Africa. J Infect Dis. 2013 Dec 15; 208 Suppl 3:S227-37.
Score: 0,113
-
Efficacy, Safety, and Immunogenicity of the MATISSE (Maternal Immunization Study for Safety and Efficacy) Maternal Respiratory Syncytial Virus Prefusion F Protein Vaccine Trial. Obstet Gynecol. 2025 Feb 01; 145(2):157-167.
Score: 0,061
-
Global genetic diversity of human metapneumovirus fusion gene. Emerg Infect Dis. 2004 Jun; 10(6):1154-7.
Score: 0,058
-
Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus Vaccine (RSVPreF3) in Mothers and Their Infants: A Phase 2 Randomized Trial. J Infect Dis. 2023 08 11; 228(3):299-310.
Score: 0,055